HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Elite 50% OFF Act now – get top investing tools Register Now!
Market News Stocks News ETF News Crypto News

Palvella Therapeutics Inc.

Contributing Author

Recent Articles by Palvella Therapeutics Inc.

Nov-11
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
Nov-06
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference PVLA GlobeNewswire
Nov-05
Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies PVLA GlobeNewswire
Nov-04
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 PVLA GlobeNewswire
Oct-13
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
Sep-24
Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies PVLA GlobeNewswire
Sep-17
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy PVLA GlobeNewswire
Sep-15
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations PVLA GlobeNewswire
Sep-03
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer PVLA GlobeNewswire
Aug-28
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences PVLA GlobeNewswire
Aug-14
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
Aug-07
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 PVLA GlobeNewswire
Aug-05
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference PVLA GlobeNewswire
Jun-30
Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes PVLA GlobeNewswire
Jun-23
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% PVLA GlobeNewswire
Jun-18
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors PVLA GlobeNewswire
Jun-09
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
May-27
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer PVLA GlobeNewswire
May-15
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
May-08
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 PVLA GlobeNewswire
May-05
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 PVLA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.